Apollomics (APLM) Competitors $6.50 -0.06 (-0.84%) Closing price 02:27 PM EasternExtended Trading$6.50 0.00 (0.00%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. ENLV, INKT, COEP, SXTC, SCYX, NRSN, TPST, CARA, TENX, and LSTAShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Enlivex Therapeutics (ENLV), MiNK Therapeutics (INKT), Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), SCYNEXIS (SCYX), NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Its Competitors Enlivex Therapeutics MiNK Therapeutics Coeptis Therapeutics China SXT Pharmaceuticals SCYNEXIS NeuroSense Therapeutics Tempest Therapeutics Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Enlivex Therapeutics (NASDAQ:ENLV) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Is ENLV or APLM more profitable? Apollomics' return on equity of 0.00% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -57.67% -50.52% Apollomics N/A N/A N/A Do institutionals & insiders believe in ENLV or APLM? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher earnings & valuation, ENLV or APLM? Enlivex Therapeutics has higher earnings, but lower revenue than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.78Apollomics$1.49M4.80-$53.86MN/AN/A Which has more risk and volatility, ENLV or APLM? Enlivex Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Does the media prefer ENLV or APLM? In the previous week, Enlivex Therapeutics' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score. Company Overall Sentiment Enlivex Therapeutics Neutral Apollomics Neutral Do analysts recommend ENLV or APLM? Enlivex Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 751.06%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Apollomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Apollomics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryEnlivex Therapeutics beats Apollomics on 6 of the 11 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.16M$2.89B$5.49B$9.01BDividend YieldN/A2.64%5.39%4.09%P/E RatioN/A21.5627.4320.06Price / Sales4.80281.29398.25108.31Price / CashN/A41.4736.1356.90Price / Book1.457.518.085.67Net Income-$53.86M-$55.05M$3.16B$248.47M7 Day Performance1.48%3.16%2.12%2.90%1 Month Performance0.23%5.92%4.43%5.75%1 Year Performance-65.76%5.82%35.62%21.36% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics0.325 of 5 stars$6.51-0.8%N/A-67.0%$7.16M$1.49M0.0045Positive NewsENLVEnlivex Therapeutics3.1868 of 5 stars$1.12-6.7%$10.00+792.9%-14.4%$28.38MN/A-1.7070Positive NewsINKTMiNK Therapeutics3.2755 of 5 stars$7.34+5.2%$37.50+410.9%-18.3%$27.82MN/A-2.9130COEPCoeptis Therapeutics0.2828 of 5 stars$7.80+0.3%N/A+36.0%$27.34MN/A-1.342Gap UpSXTCChina SXT Pharmaceuticals0.1469 of 5 stars$1.73+0.6%N/A-79.4%$27.22M$1.82M0.0090SCYXSCYNEXIS0.2618 of 5 stars$0.67-2.4%N/A-63.1%$26.98M$3.75M-1.2060NRSNNeuroSense Therapeutics1.7256 of 5 stars$1.89-0.5%$14.00+640.7%+53.2%$25.97MN/A-3.5010News CoverageGap DownTPSTTempest Therapeutics1.8001 of 5 stars$6.80-1.4%$30.00+341.2%-74.1%$25.41MN/A-0.3820News CoverageCARACara Therapeutics0.3739 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.3134 of 5 stars$5.76-1.5%$17.50+203.8%+81.1%$24.27MN/A-2.329LSTALisata Therapeutics2.4131 of 5 stars$2.90+3.6%$15.00+417.2%-21.1%$24.12M$1M-1.2630 Related Companies and Tools Related Companies Enlivex Therapeutics Competitors MiNK Therapeutics Competitors Coeptis Therapeutics Competitors China SXT Pharmaceuticals Competitors SCYNEXIS Competitors NeuroSense Therapeutics Competitors Tempest Therapeutics Competitors Cara Therapeutics Competitors Tenax Therapeutics Competitors Lisata Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
